Findings from a meta-analysis included five studies containing 2546 breast cases indicating that PD-L1 expression in tumor tissues could be a valuable biomarker for breast cancer prognosis and patient selection for immunotherapy [23]. This evidence concerns the gene CD274 and breast carcinoma.